Some key tumor progression-associated genes like PTEN in astrocytoma and in embryonal tumors, MYCN in ependymoma, and BRCA2 in glioneuronal/neuronal tumors would not otherwise have been identified as significantly differentially expressed in the tumors had the cell type proportions not been adjusted for. This evidence concerns the gene BRCA2 and neoplasm.